E

East Coast Institute for Research | Canton, GA

Research site

(Unclaimed)

Location

125 Oakside Court, Suite 301, Canton, Georgia, United States of America

Site insights

Top conditions

Top treatments

RTA 901

Cadisegliatin

Olpasiran

BW-00112

BIIB143

Parent organization

This site is a part of East Coast Institute for Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 8 total trials

A Study in Patients With Mixed Dyslipidemia

A Phase 2 in Patients With Mixed Dyslipidemia

Enrolling

Mixed Dyslipidemia

Drug: BW-00112

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes (CATT1)

This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.

Enrolling

Diabetes Mellitus, Type 1

Drug: Cadisegliatin 800 mg QD

Drug: Placebo

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardi...

Enrolling

Cardiovascular Disease

Drug: Olpasiran

Drug: Placebo

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec (OPTI-2)

The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in...

Active, not recruiting

Diabetes Mellitus, Type 1

Drug: Lispro

Drug: HDV-Lispro